The Asia Pacific Gabapentin Market should witness market growth of 5.2% CAGR during the forecast period (2022-2028).
Gabapentin still remains one of the most prescribed medicines to treat chronic pain. Although chronic painfrequently develops due to an illness or injury, it is a distinct condition in and of itself and not merely a symptom of other illnesses. As a result, chronic pain has a distinct taxonomy and medical description. Recurrent tension-type headaches are one ofthe most prevalent symptomatic chronic diseases, affecting 1.9 billion people worldwide and contributing to the growing burden of chronic pain.
Neck andlow back pain have continuously been the primary causes of disability, accounting for the majority of years lived with disability, with other chronic pain diseases making significant appearances in the top 10. An episode of shingles can result in postherpetic neuralgia. According to the CDC, approximately10% to 18% of people with shingles develop postherpetic neuralgia. The FDA has only approved using gabapentin under the trade name Gralise to manage postherpetic neuralgia (PHN). An extended-release medication called Horizant (gabapentin enacarbil) is prescribed to treat adults with PHNand restless legs syndrome.
Chronic pain isone of the most important healthcare concerns in the region as the proportion of the aging population and the frequency of associated illnesses rises. Additionally, notwithstanding the Southeast Asian nations' achievements in sustainable health care and forward-thinking economic growth, controlling epilepsy is still difficult because of the huge cultural, racial, and political variety among its population. This can be considered a management gap, diagnostic accuracy &facilities gaps, medical &surgical treatment gaps, and stigma reduction gaps. The burden of these health issues is increasing the demand for gabapentin drugs significantly. Therefore, in the coming years, the region presents lucrative growth opportunities for the gabapentin market.
The China market dominated the Asia Pacific Gabapentin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $203.6 million by 2028. The Japan market is estimated to grow a CAGR of 4.6% during (2022-2028). Additionally, The India market would experience a CAGR of 5.9% during (2022-2028).
Based on Application, the market is segmented into Epilepsy, Restless Legs Syndrome, Neuropathic Pain, and Others. Based on Dosage Form, the market is segmented into Capsule, Tablet and Oral Solution. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
Gabapentin still remains one of the most prescribed medicines to treat chronic pain. Although chronic painfrequently develops due to an illness or injury, it is a distinct condition in and of itself and not merely a symptom of other illnesses. As a result, chronic pain has a distinct taxonomy and medical description. Recurrent tension-type headaches are one ofthe most prevalent symptomatic chronic diseases, affecting 1.9 billion people worldwide and contributing to the growing burden of chronic pain.
Neck andlow back pain have continuously been the primary causes of disability, accounting for the majority of years lived with disability, with other chronic pain diseases making significant appearances in the top 10. An episode of shingles can result in postherpetic neuralgia. According to the CDC, approximately10% to 18% of people with shingles develop postherpetic neuralgia. The FDA has only approved using gabapentin under the trade name Gralise to manage postherpetic neuralgia (PHN). An extended-release medication called Horizant (gabapentin enacarbil) is prescribed to treat adults with PHNand restless legs syndrome.
Chronic pain isone of the most important healthcare concerns in the region as the proportion of the aging population and the frequency of associated illnesses rises. Additionally, notwithstanding the Southeast Asian nations' achievements in sustainable health care and forward-thinking economic growth, controlling epilepsy is still difficult because of the huge cultural, racial, and political variety among its population. This can be considered a management gap, diagnostic accuracy &facilities gaps, medical &surgical treatment gaps, and stigma reduction gaps. The burden of these health issues is increasing the demand for gabapentin drugs significantly. Therefore, in the coming years, the region presents lucrative growth opportunities for the gabapentin market.
The China market dominated the Asia Pacific Gabapentin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $203.6 million by 2028. The Japan market is estimated to grow a CAGR of 4.6% during (2022-2028). Additionally, The India market would experience a CAGR of 5.9% during (2022-2028).
Based on Application, the market is segmented into Epilepsy, Restless Legs Syndrome, Neuropathic Pain, and Others. Based on Dosage Form, the market is segmented into Capsule, Tablet and Oral Solution. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
Scope of the Study
By Application
- Epilepsy
- Restless Legs Syndrome
- Neuropathic Pain
- Others
By Dosage Form
- Capsule
- Tablet
- Oral Solution
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Zydus Lifesciences Ltd.
- Glenmark Pharmaceuticals Limited
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Alkem Laboratories Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Aurobindo Pharma Limited
- Amneal Pharmaceuticals, Inc.
- Cipla Limited
- Apotex, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Gabapentin Market by Application
Chapter 4. Asia Pacific Gabapentin Market by Dosage Form
Chapter 5. Asia Pacific Gabapentin Market by Distribution Channel
Chapter 6. Asia Pacific Gabapentin Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Zydus Lifesciences Ltd.
- Glenmark Pharmaceuticals Limited
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Alkem Laboratories Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Aurobindo Pharma Limited
- Amneal Pharmaceuticals, Inc.
- Cipla Limited
- Apotex, Inc.
Methodology
LOADING...
Related Reports
Gabapentin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F
- Report
- 185 Pages
- Global
From
Gabapentin Market - Forecasts from 2024 to 2029
- Report
- 144 Pages
- Global
From
From
Gabapentin (CAS 60142-96-3) Global Market Research Report 2024
- Report
- 50 Pages
- Global
From
Gabapentin enacarbil (CAS 478296-72-9) Global Market Research Report 2024
- Report
- 50 Pages
- Global
From
About the Gabapentin Market
Gabapentin is a medication used to treat certain types of seizures and nerve pain. It is a central nervous system (CNS) drug, meaning it acts on the brain and spinal cord to produce its effects. It is used to treat epilepsy, neuropathic pain, hot flashes, and restless leg syndrome. It is also used off-label to treat anxiety and insomnia. Gabapentin is generally well-tolerated, but can cause side effects such as dizziness, drowsiness, and confusion. Gabapentin is available in both generic and Read more
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
